Rights and permissions
About this article
Cite this article
Imatinib mesylate: preferred drug for CML?. Inpharma Wkly. 1409, 16 (2003). https://doi.org/10.2165/00128413-200314090-00037
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200314090-00037